Hope for Vision Restoration

Developing a Breakthrough Treatment for Glaucoma



Company Overview

- NurExone is developing **breakthrough exosome-based therapies** to **regenerate** nerves and **recover** function in debilitating conditions. The therapies leverage the **natural healing power** of exosomes, which are derived from human stem cells and loaded with **therapeutic molecules**.
- Our lead product therapy, Exo-PTEN, is being developed for **multiple high-impact neuronal indications**, including optic nerve degeneration in glaucoma and other eye diseases, acute spinal cord injury, and facial nerve paralysis.
- All indications have shown **preclinical evidence** of **nerve regeneration** and **functional recovery**.

The Urgent Need in Glaucoma: Restoring Lost Vision

- Glaucoma is a leading cause of irreversible blindness worldwide, affecting about **80 million people globally**. Current treatments mainly focus on lowering intraocular pressure to slow disease progression, but they cannot address or reverse optic nerve damage or restore lost vision.
- There is a **profound unmet medical need** for a therapy that can regenerate a damaged optic nerve and offer hope for recovery of vision.
- The **global economic burden** of blindness and visual impairment is substantial, creating an immense market opportunity for an effective regenerative solution.
- **Prof. Michael Belkin**, a globally recognized award-winning expert in ophthalmology and glaucoma, serves as a scientific advisor, helping guide clinical translation of Exo-PTEN for optic nerve regeneration.

Exo-PTEN: Our Flagship Product for Optic Nerve Regeneration

For glaucoma treatment, Exo-PTEN is designed for:

- **Optic Nerve Regeneration:** Directly targets and facilitates the regeneration of damaged optic nerve fibers.
- **Vision Recovery:** Preclinical studies with a leading global hospital have shown remarkable potential, with more than **75% functional recovery and optic nerve healing demonstrated in animal models** of glaucoma.
- **Minimal-Invasive Administration:** By simple injection

Preclinical Data Suggests Optic Nerve Healing and Vision Restoration



A-left side-normal, **B**-middle-damaged, **C**-right side-after treatment,

- **Optical Nerve Crush (ONC)** - a standard animal model which mimic the glaucoma nerve damage by causing pressure leading to death of neurons at the optic nerve.



ONC in one eye treated with ExoPTEN (green, ONC+PTEN), resulting in a retinal response similar to the healthy intact contralateral eye grey)

- Large scale preclinical study underway at Sheba Medical Center (ranked as the 8th best hospital globally in 2025 by Newsweek)

Drug Delivery by Exosome

Where Nature Ends, NurExone Begins

Company Status & Vision

- NurExone Biologic is a **publicly traded company**, listed on the TSXV (NRX.V) in Canada and quoted on Germany (J90.F) and OTCQB (NRXBF). To date, the company has raised ~$17 Million (USD), fueling its robust development and product roadmap.
- Expanding operational presence in the U.S. with an **Exclusive Master Cell Bank** owned by a fully owned subsidiary to produce **clinical grade exosomes** for our therapies and for **aesthetic use** as **a source of additional revenue** from the cosmetic industry.
- Advancing plans to uplist to **a major U.S. stock exchange.**

NurExone Biologic:
Where Nature Ends, NurExone Begins
For more information, please contact:
info@nurexone.com
TSXV: NRX | OTCQB: NRXBF

Disclaimer

The matters discussed in this document are forward-looking statements that involve a number of risks and uncertainties.

The actual future results of the company could differ significantly from those statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.

This document does not constitute an offer to sell or a solicitation of offers to buy any securities of the company or any entity.

For references, please visit - https://www.sedarplus.ca/landingpage/ , then at the select profile, please write NurExone.

What Are Exosomes?

- Naturally occurring **nanoparticles** with **inherent healing**, **regenerative**, and **intercellular communication** capabilities. They can be used to **deliver therapeutic cargo** directly to damaged tissues through minimally invasive administration. As acellular vesicles, exosomes avoid the risks associated with live cell therapies.

NurExone: Regenerate. Rewire. Recover

- Using our ExoTherapy platform, we load exosomes with therapeutic molecules to create therapies that **regenerate** nerves, **rewire** connections and support **recovery**.
- NurExone's lead product under development, Exo-PTEN, **harnesses the power** of exosomes to deliver targeted siRNA cargo that inhibits PTEN expression.



ExoTherapy Advantage: Superior Technology for Broad Impact

ExoTherapy platform offers significant advantages over conventional and cell-based therapies:

- **Cell-Free Approach:** eliminating the risks associated with live cell transplantation (e.g., immune rejection, tumorigenicity).
- **Targeted & Efficient Delivery:** Exosomes naturally home to sites of injury and can effectively cross biological barriers, including the blood-brain barrier.
- **Off the shelf product:** Ease of production, distribution, and point of administration.
- **Minimally Invasive Drug Administration:** Due to the natural affinity of Exosomes to inflamed or damaged tissues.